Hepatitis Screening

The General Hepatitis Panel Test screens for multiple hepatitis infections in one order. It includes Hepatitis A Antibody Total, Hepatitis B Surface Antibody Qualitative, Hepatitis B Surface Antigen with Reflex to Confirmation, Hepatitis B Core Antibody Total, and Hepatitis C Antibody with Reflex to RNA PCR. Doctors use this panel to detect past exposure, confirm active or chronic infection, guide treatment, and support liver health monitoring.

The Hepatitis A Antibody Total Test is a qualitative test that detects antibodies to hepatitis A virus (HAV) and reports results as Reactive or Non-Reactive. It does not distinguish between IgM and IgG antibodies. A reactive result may indicate past infection or immunity from vaccination, while a non-reactive result suggests no prior exposure. Doctors use this test to assess immune status, guide vaccination decisions, and evaluate risk of hepatitis A infection.

The Hepatitis A IgM Antibody Test is a qualitative blood test that detects IgM antibodies to the hepatitis A virus (HAV) and reports results as Reactive or Non-Reactive. A reactive result usually indicates a recent or current hepatitis A infection, while a non-reactive result means no active infection. Doctors use this test to confirm acute hepatitis A in patients with symptoms like jaundice, nausea, fatigue, or abdominal pain and to guide timely treatment and prevention.

The Hepatitis B Core IgM Antibody Test is a qualitative test that detects IgM antibodies to the hepatitis B core antigen (anti-HBc IgM) and reports results as Reactive or Non-Reactive. A reactive result indicates a recent or acute hepatitis B infection, while a non-reactive result suggests no active infection. Doctors order this test to confirm acute hepatitis B in patients with symptoms such as jaundice, fatigue, fever, or abdominal pain and to guide treatment and monitoring.

The Hepatitis B Core Antibody Total Test is a qualitative blood test that detects antibodies to the hepatitis B core antigen (anti-HBc) and reports results as Reactive or Non-Reactive. A reactive result may indicate past or ongoing infection, while a non-reactive result suggests no exposure. This test does not distinguish between IgM and IgG antibodies. Doctors use it to evaluate hepatitis B exposure, confirm infection history, and assess overall immune response.

The Hepatitis B Surface Antibody Qualitative Test detects anti-HBs antibodies to the hepatitis B surface antigen and reports results as Reactive or Non-Reactive. A reactive result indicates past exposure, either from hepatitis B infection or prior vaccination, while a non-reactive result suggests no detectable exposure. Doctors use this test to confirm hepatitis B exposure history, evaluate vaccine response, and guide further preventive or diagnostic decisions.

The Hepatitis B Surface Antibody Quantitative Test measures the exact level of anti-HBs antibodies in blood to determine past exposure and whether protective immunity has developed from infection or vaccination. A higher antibody level generally indicates adequate immune response, while a low level suggests limited or no protection. Doctors use this test to confirm vaccine effectiveness, assess immune status, and support hepatitis B screening or preventive care.

The Hepatitis B Surface Antigen (HBsAg) Test with Reflex to Confirmation screens for hepatitis B surface antigen in blood and, if reactive, automatically performs confirmatory testing. A reactive confirmed result indicates an active hepatitis B infection, while a non-reactive result shows no infection. Doctors use this test to diagnose acute or chronic hepatitis B, investigate abnormal liver tests, and guide treatment, monitoring, and infection control decisions.

The Hepatitis Be Antibody (anti-HBe) Test is a qualitative blood test that detects antibodies to the hepatitis B e antigen and reports results as Reactive or Non-Reactive. A reactive result often indicates lower infectivity and a transition toward recovery or inactive disease, while a non-reactive result suggests no antibodies were detected. Doctors use this test to monitor hepatitis B infection stage, evaluate treatment response, and support long-term disease management.

The Hepatitis Be Antigen (HBeAg) Test is a qualitative blood test that detects the presence of hepatitis B e antigen and reports results as Reactive or Non-Reactive. A reactive result suggests active viral replication and high infectivity, while a non-reactive result indicates no HBeAg detected. Doctors use this test to evaluate hepatitis B disease stage, monitor treatment effectiveness, and assess risk of transmission, supporting long-term infection management.

The Hepatitis C Antibody with HCV RNA Quantitative PCR test is a comprehensive diagnostic test used to detect and confirm the presence of the Hepatitis C virus (HCV) in the blood. It combines the initial screening for HCV antibodies with a quantitative polymerase chain reaction (PCR) test to measure the viral load.

 The Hepatitis C Antibody & Liver Function Panel is a comprehensive diagnostic tool used to detect the presence of hepatitis C virus (HCV) antibodies and assess liver function. This panel includes the Hepatitis C Antibody with Reflex to Quantitative HCV RNA PCR test, along with a series of liver function tests: Albumin, Albumin/Globulin Ratio, Alkaline Phosphatase, Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Bilirubin Direct, Bilirubin Indirect, Bilirubin Total, Globulin, and Protein Total. This panel is crucial for diagnosing HCV infection and evaluating the liver's health and functionality.

The Hepatitis C Viral RNA Quantitative Test measures the amount of hepatitis C virus (HCV) RNA in blood to determine viral load. This test confirms active infection, evaluates disease severity, and monitors response to antiviral therapy. High viral load indicates significant viral replication, while lower or undetectable levels suggest effective treatment or controlled infection. Doctors use this test to guide therapy, track progress, and manage long-term liver health.

The Acetylcholine Receptor Binding Antibody Test detects antibodies targeting acetylcholine receptors, a hallmark of myasthenia gravis. This autoimmune disorder affects nerve-to-muscle communication, causing weakness and fatigue. The test helps confirm diagnosis, differentiate from other neuromuscular diseases, and guide treatment. Elevated antibody levels support early detection and ongoing management of myasthenia gravis.

The Acetylcholine Receptor Blocking Antibody Test evaluates autoantibodies that block acetylcholine receptors, impairing nerve-to-muscle signaling. It is commonly ordered in the workup of suspected myasthenia gravis, where these antibodies contribute to muscle fatigue and weakness. This test, often performed with AChR binding and modulating antibody assays, provides valuable insight into autoimmune mechanisms affecting neuromuscular transmission.

The Acetylcholine Receptor Modulating Antibody Test measures autoantibodies that cause loss or alteration of acetylcholine receptors on muscle cells, impairing nerve transmission. Elevated levels are commonly linked to myasthenia gravis, an autoimmune disorder causing muscle weakness. This test aids in identifying immune-mediated neuromuscular disease and helps evaluate disease severity.

The Actin Smooth Muscle IgG Antibody Test detects autoantibodies against smooth muscle actin, often linked to autoimmune hepatitis and chronic liver disease. Elevated levels may indicate liver inflammation, cirrhosis, or other autoimmune conditions. Doctors use this blood test with liver panels and additional antibody tests to aid in diagnosis, monitor disease progression, and guide treatment decisions for patients with suspected autoimmune liver disorders.

The Ammonia Plasma Test measures ammonia levels in blood to evaluate liver function and metabolic health. Elevated ammonia may result from liver disease, cirrhosis, Reye’s syndrome, or urea cycle disorders, causing confusion or altered mental status. Doctors order this test for patients with unexplained behavioral changes, lethargy, or suspected hepatic encephalopathy. Results provide key insight into liver function, metabolic disorders, and treatment monitoring.

The ANA Screen IFA with Reflex to Titer and Pattern Test detects antinuclear antibodies in blood to evaluate autoimmune activity. If positive, further testing identifies antibody concentration (titer) and fluorescence pattern, helping diagnose conditions like lupus, rheumatoid arthritis, or Sjögren’s syndrome. Doctors order this test to investigate symptoms such as joint pain, fatigue, rash, or swelling and to guide treatment for autoimmune and connective tissue disorders.

The ANA IFA Panel Comprehensive screens for autoimmune disorders by detecting antinuclear antibodies and specific markers including dsDNA, Sm, Sm/RNP, Scl-70, and Sjögren’s SS-A/SS-B. Doctors order this panel for patients with joint pain, rash, fatigue, or suspected lupus, scleroderma, or Sjögren’s syndrome. Results provide critical insight into autoimmune activity, helping confirm diagnosis, monitor disease progression, and guide treatment decisions.

The Complement Component C3c Test measures levels of C3c, a protein involved in the immune complement system. Abnormal results may indicate autoimmune disorders, recurrent infections, or kidney disease linked to immune activity. Doctors use this blood test to evaluate complement activation, diagnose immune-related conditions, and monitor disease progression or treatment effectiveness in patients with suspected lupus, glomerulonephritis, or other immune disorders.

The Complement Total CH50 Test measures overall activity of the complement system, a key part of the immune response that helps fight infections and regulate inflammation. Abnormal results may indicate autoimmune diseases such as lupus, complement deficiencies, or immune complex disorders. Doctors use this blood test to evaluate immune function, investigate recurrent infections, and monitor treatment in patients with suspected immune or autoimmune conditions.